A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.

• Status: Completed
• Trial end date: 1999-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Mercilon.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: Contraceptive Agents; Dacuronium; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Norelgestromin; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Healthy women with regular menstrual cycles

• sexually active and at risk of pregnancy

• nonpregnant

• acceptable body mass index (BMI)

• last term pregnancy at least 42 days prior, nonlactating, with 1 normal menstrual cycle since

• sitting BP<140mmHg/<90mmHg

• 1 normal menstrual cycle since removal of IUD or norplant

• agreement to use study drug for contraception for up to 13 cycles, except when backup contraception is required for disease protection or patch detachment

• agree not to use other systemic steroid medication

• signed Informed Consent Form.

Exclusion Criteria:

• Presence, history, hereditary predisposition or risk of deep vein thrombophlebitis or thromboembolic disorders

• cerebral vascular or coronary artery disease, hypertension, or severe migraines

• liver tumor resulting from estrogen-containing products

• diabetes mellitus

• cholestatic jaundice, liver or renal disease

• neurovascular lesion of the eye or serious visual disturbance

• abnormal PAP smear

• undiagnosed abnormal vaginal bleeding

• thyroid disorder

• dermal hypersensitivity

• carcinoma of breast, endometrium or other estrogen-dependent neoplasia

• substance abuse

• received experimental drug or any hepatic enzyme-inducing drugs within prior 30 days

• received any depot hormone injection within prior 6 months

• smoking women over 35 years of age.